Stock Taper Operating Loss: $139.3 million, primarily due to payroll, business expenses, and professional fees, including $41.8 million in noncash stock-based compensation.
Loss Before Income Taxes: $110.2 million, with $29.1 million in interest and dividend income from marketable securities.
Cash Used in Operating Activities: $82.2 million, adjusted to $69.2 million after accounting for prepaid capital project expenses, aligning with guidance of $65 million to $80 million.
Cash and Marketable Securities: $1.4 billion at year-end 2025, with an additional $1.182 billion raised in January 2026, completing a $1.5 billion ATM program.
Guidance for 2026: Cash used in operating activities expected to increase to $80 million to $100 million; cash used in investing activities projected between $350 million and $450 million.
Project Deployment: Transitioned from product development to active project deployment, including groundbreaking on the Aurora powerhouse at Idaho National Laboratory and construction progress on the Groves radioisotope test reactor.
Partnerships: Secured a prepayment agreement with Meta for a 1.2 gigawatt power campus, enhancing project certainty and supporting fuel procurement.
Fuel Strategy: Advanced fuel capabilities, including a joint venture with Centrus for uranium deconversion and progress on the A3F fuel fabrication facility.
Isotope Business: The Idaho Radiochemistry Laboratory obtained an NRC materials license, with expectations for revenue generation in 2026.
2026 Expectations: Continued investment in projects across all three business units (power, fuel, isotopes) with a disciplined approach to cash management.
CapEx Guidance: Anticipated spending of $350 million to $450 million in 2026, with expectations for sustained investment levels into 2027.
Regulatory Environment: Positive outlook on government support and potential new programs to accelerate nuclear project timelines.
Operating Losses: Significant operating losses continue to be a concern, driven by high expenses related to project development.
Regulatory Delays: Some delays were noted due to the government shutdown affecting licensing timelines, although no significant long-term impacts were reported.
Cost Management: The need to balance project timelines with cost management remains a challenge, particularly as the company scales operations.
Market Competition: The competitive landscape is intensifying, particularly with other sodium-cooled reactor developers like TerraPower.
Commercialization Pipeline: Strong interest from potential customers, with Meta serving as a key anchor. Discussions are ongoing with other industrial and military customers.
CapEx Allocation: While specific project breakdowns were not provided, significant investments are expected in Idaho and Ohio, with a focus on fuel and recycling projects.
Regulatory Strategy: The company is pursuing different licensing pathways for various projects, with DOE authorization facilitating faster builds compared to traditional NRC licensing.
Plutonium Criticality Experiments: Successful tests were conducted, enhancing the company's understanding and modeling of fast-spectrum reactors, with expectations for further developments in plutonium allocations.
Meta Agreement: The prepayment agreement with Meta is a significant step towards securing binding power purchase agreements (PPAs), with further discussions expected to solidify these arrangements. Overall, Oklo's Q4 2025 performance reflects a strategic shift towards project execution and deployment, with a strong financial position to support growth, despite ongoing operational challenges and competitive pressures in the nuclear sector.
SOURCE: Q4 2025 EARNINGS CALL TRANSCRIPT